Decitabine for acute myeloid leukemia in a patient undergoing hemodialysis

Taxiarchis V. Kourelis, M. N. Moustakakis, R. Silk, D. Pharm, A. Boruchov, S. F. Bilgrami

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Treatment of patients with Acute Myeloid Leukemia (AML) undergoing hemodialysis is especially challenging since there are no specific management guidelines for the administration of cytotoxic agents in these patients. Well established chemotherapy protocols may be unsuitable in such cases because of altered drug pharmacokinetics, increased risk for complications, and underlying co-morbidities. In addition, these patients are at an increased risk for complications such as tumor lysis syndrome. Herein, we report the first use of decitabine in a patient on hemodialysis. He presented with a new diagnosis of AML and achieved hematologic remission following the use of induction chemotherapy and maintenance decitabine.

Original languageEnglish (US)
Pages (from-to)289-292
Number of pages4
JournalEuropean Journal of Inflammation
Issue number3
StatePublished - 2011


  • Acute myeloid leukemia
  • Decitabine
  • Hemodialysis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Decitabine for acute myeloid leukemia in a patient undergoing hemodialysis'. Together they form a unique fingerprint.

Cite this